Jim Simons’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.7M | Buy |
1,663,835
+73,700
| +5% | +$1.08M | 0.04% | 566 |
|
|
2025
Q4 | $25.4M | Buy |
1,590,135
+140,535
| +10% | +$1.99M | 0.04% | 500 |
|
|
2025
Q3 | $16M | Buy |
1,449,600
+291,800
| +25% | +$3.19M | 0.02% | 842 |
|
|
2025
Q2 | $9.81M | Buy |
1,157,800
+219,200
| +23% | +$1.76M | 0.01% | 1065 |
|
|
2025
Q1 | $7.55M | Buy |
938,600
+237,700
| +34% | +$1.93M | 0.01% | 1169 |
|
|
2024
Q4 | $6.29M | Buy |
700,900
+214,200
| +44% | +$1.75M | 0.01% | 1300 |
|
|
2024
Q3 | $3.57M | Buy |
486,700
+285,200
| +142% | +$1.77M | 0.01% | 1663 |
|
|
2024
Q2 | $1.15M | Sell |
201,500
-43,100
| -18% | -$227K | ﹤0.01% | 2245 |
|
|
2024
Q1 | $1.23M | Buy |
244,600
+109,600
| +81% | +$743K | ﹤0.01% | 2355 |
|
|
2023
Q4 | $1.21M | Sell |
135,000
-528,000
| -80% | -$4.35M | ﹤0.01% | 2272 |
|
|
2023
Q3 | $5.15M | Sell |
663,000
-867,400
| -57% | -$8.48M | 0.01% | 1290 |
|
|
2023
Q2 | $14.8M | Sell |
1,530,400
-53,800
| -3% | -$558K | 0.02% | 823 |
|
|
2023
Q1 | $17.4M | Sell |
1,584,200
-69,000
| -4% | -$608K | 0.02% | 798 |
|
|
2022
Q4 | $7.14M | Buy |
1,653,200
+919,400
| +125% | +$5.33M | 0.01% | 1283 |
|
|
2022
Q3 | $5.52M | Buy |
733,800
+135,200
| +23% | +$1.17M | 0.01% | 1367 |
|
|
2022
Q2 | $6.02M | Sell |
598,600
-1,095,600
| -65% | -$12.2M | 0.01% | 1426 |
|
|
2022
Q1 | $21M | Buy |
1,694,200
+1,227,129
| +263% | +$19M | 0.02% | 738 |
|
|
2021
Q4 | $10.7M | Buy |
+467,071
| New | +$11.1M | 0.01% | 1029 |
|
|
2020
Q4 | – | Sell |
-239,400
| Closed | -$3.53M | – | 3374 |
|
|
2020
Q3 | $3.53M | Sell |
239,400
-918,100
| -79% | -$13.3M | ﹤0.01% | 1776 |
|
|
2020
Q2 | $18.8M | Sell |
1,157,500
-281,300
| -20% | -$4.5M | 0.02% | 853 |
|
|
2020
Q1 | $20.9M | Buy |
1,438,800
+860,266
| +149% | +$15.2M | 0.02% | 748 |
|
|
2019
Q4 | $11.7M | Buy |
578,534
+567,789
| +5,284% | +$5.23M | 0.01% | 1346 |
|
|
2019
Q3 | $57K | Sell |
10,745
-57,878
| -84% | -$350K | ﹤0.01% | 3318 |
|
|
2019
Q2 | $452K | Sell |
68,623
-111,077
| -62% | -$708K | ﹤0.01% | 3032 |
|
|
2019
Q1 | $1.17M | Buy |
+179,700
| New | +$1.19M | ﹤0.01% | 2604 |
|
|
2018
Q1 | – | Sell |
-53,001
| Closed | -$242K | – | 3360 |
|
|
2017
Q4 | $242K | Sell |
53,001
-5,300
| -9% | -$29.4K | ﹤0.01% | 3084 |
|
|
2017
Q3 | $366K | Sell |
58,301
-12,700
| -18% | -$80.1K | ﹤0.01% | 2862 |
|
|
2017
Q2 | $435K | Sell |
71,001
-34,699
| -33% | -$234K | ﹤0.01% | 2798 |
|
|
2017
Q1 | $776K | Buy |
+105,700
| New | +$488K | ﹤0.01% | 2630 |
|
|
2016
Q4 | – | Sell |
-85,100
| Closed | -$256K | – | 3238 |
|
|
2016
Q3 | $256K | Buy |
85,100
+44,000
| +107% | +$119K | ﹤0.01% | 3004 |
|
|
2016
Q2 | $114K | Buy |
41,100
+10,700
| +35% | +$29.2K | ﹤0.01% | 3140 |
|
|
2016
Q1 | $88K | Sell |
30,400
-6,800
| -18% | -$16.4K | ﹤0.01% | 3229 |
|
|
2015
Q4 | $92K | Buy |
+37,200
| New | +$101K | ﹤0.01% | 3120 |
|
Other funds holding AUPH
TCM
NMC
Jim Simons's AUPH Position: Q1 2026 in Review
Jim Simons increased its Aurinia Pharmaceuticals (AUPH) stake by 4.6% in Q1 2026, buying an estimated $1.08M and bringing the position to 1,663,835 shares worth $24.7M. The position accounts for 0.04% of the portfolio, ranked #566.
Jim Simons first reported a position in AUPH in Q4 2015 and has held it in 33 quarters since. The position peaked at $25.4M in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.
- Jim Simons held 1,663,835 shares of Aurinia Pharmaceuticals worth $24.7M as of Q1 2026.
- Jim Simons bought 73,700 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $1.08M.
- Aurinia Pharmaceuticals made up 0.04% of Jim Simons's portfolio in Q1 2026, its #566 holding.
- Jim Simons first reported a position in Aurinia Pharmaceuticals in Q4 2015 and has held it in 33 quarters since.
- Jim Simons's Aurinia Pharmaceuticals position peaked at $25.4M in Q4 2025.
- 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.